For decades, the search for the brain’s appetite control mechanism focused almost exclusively on neurons — the cells that fire electrical signals and are assumed to run the show. Astrocytes, the star-shaped cells that surround neurons, were dismissed as mere support staff. Housekeepers. Background players.
A new study from the University of Maryland has upended that assumption entirely.
The Chain That Signals “Full”
The research, published April 6 in the Proceedings of the National Academy of Sciences, reveals a previously unknown signaling chain that begins the moment glucose rises in the blood after a meal.
Deep inside the brain, specialized cells called tanycytes line a fluid-filled cavity and monitor glucose levels in the cerebrospinal fluid. When glucose rises after eating, tanycytes metabolize it and release a byproduct — lactate — into the surrounding brain tissue.
That lactate then reaches neighboring astrocytes, which express a specialized receptor called HCAR1. When lactate binds to HCAR1, the astrocytes activate and release glutamate — a chemical signal that reaches the appetite-suppressing neurons in the hypothalamus, triggering the feeling of fullness.
The finding reveals that astrocytes are not passive bystanders. They are active participants in one of the body’s most fundamental survival processes: knowing when to stop eating.
A Dual Brake System
The hypothalamus contains two opposing populations of neurons: those that promote hunger and those that suppress it. The study found that lactate can work on both simultaneously — activating fullness neurons through the astrocyte pathway, while potentially quieting hunger neurons through a more direct route.
This dual mechanism suggests the brain’s appetite regulation system is far more sophisticated — and far more dependent on non-neuronal cells — than previously understood.
Beyond Ozempic
The discovery opens an entirely new class of potential drug targets for obesity treatment. Rather than targeting neurons directly — as existing appetite drugs do — future therapies could target the astrocyte HCAR1 receptor specifically.
“We now have a different mechanism where we might be able to target astrocytes or specifically this HCAR1 receptor,” the researchers noted. “It would be a novel target that may complement existing therapies like Ozempic and improve the lives of many who suffer from obesity and other appetite-related conditions.”
In a world where obesity affects more than a billion people globally, the discovery that the brain’s “stop eating” signal was hiding in cells that scientists had overlooked for generations carries a certain poetic weight. The answer, it turns out, was never missing. It was simply in the wrong cell type.
